Medidata financials strong despite NCI contract termination

In a financial statement last week, e-clinical solutions provider Medidata reports record revenues, margins and profitability thanks in part to "brisk sales" to mid-size biopharma companies, especially in Asia Pacific. The company reports also a $3.2-million "one-time acceleration of revenue recognition related to a contractual termination" on behalf of the National Cancer Institute." According to Reuters, the NCI had terminated its contract with Medidata late last year. The contract had been under review with the Government Accountability Office after a competitor had protested about the bidding. Release | Report

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.